Sage Therapeutics
Following a meeting with the U.S. Food and Drug Administration Sage Therapeutics is seeing the goal line for potential expedited approval of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Sage Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for brexanolone (SAGE-547) to treat postpartum depression (PPD).
Martin Shkreli’s actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate.
A look at three small biotechs that big drugmakers are drooling over.
During the J.P. Morgan Healthcare Conference, Sage provided an update on its long-term strategy to drive growth at the company.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
JOBS
IN THE PRESS